Hi-HIS推广顺利，与飞利浦合作持续深入

Investment Rating - The investment rating for the company is "Buy" [23][30]. Core Insights - The company has shown significant growth in its software sales, achieving revenue of 683 million RMB, a year-on-year increase of 20.18%, driven by the maturity of products like Hi-HIS and an optimized customer structure [2]. - The company secured 29 software orders exceeding 10 million RMB in the smart hospital and public health sectors, totaling nearly 500 million RMB [2]. - The sales of the company's smart medical insurance systems increased by 204.58%, with the contract number for the DRG/DIP product line growing by 217.39% and the collection amount increasing by 463.43% [2]. - The company is expected to achieve revenues of 2.023 billion RMB, 2.555 billion RMB, and 3.241 billion RMB for the years 2024, 2025, and 2026, respectively, with growth rates of 25.20%, 26.31%, and 26.82% [23][26]. Summary by Sections Performance Review - In 2023, the company reported total revenue of 1.616 billion RMB, a 5.81% increase year-on-year, and a net profit attributable to shareholders of 37 million RMB, a decrease of 13.93% [22]. Business Analysis - The company has successfully launched the CTasy 1.0 electronic medical record product in collaboration with Philips, which is expected to become a new growth engine [23]. - The partnership with Philips extends beyond software sales to include medical device sales and agency services [23]. Profit Forecast - The forecast for net profit attributable to shareholders is 311 million RMB, 417 million RMB, and 515 million RMB for 2024, 2025, and 2026, respectively, with substantial growth rates of 746.42%, 34.35%, and 23.35% [23][26].